PubMed Health⌕ Search

Biomedical subjects

V I Metelitsa

Publications and source records attributed to V I Metelitsa.

At least 91 records · Page 5Linked to original sources
PubMed1987

[Comparative evaluation of the effectiveness of individually adjusted doses of trinitrolong, sustac and nitroderm in long-term use in patients with stenocardia].

The efficiency of long-term intermittent use of trinitrolong (TNL) and continuous oral use of sustac (ST) was compared in 44 patients with angina of effort, showing particularly good response to long-acting nitrates, as evidenced by paired bicycle ergometric tests. The efficacy of nitroderm (ND) adhesive tape applied on the skin was also assessed in 10 patients. TNL had better antianginal effect, and allowed a higher stress tolerance level, as compared to ST. ND was inferior to TNL and ST in terms of efficiency, apparently due to rapidly developing tolerance to its antianginal effect.

Administration, Cutaneous↗
PubMed1987

System approach to testing hypotensive drugs for prevention of arterial hypertension.

Long-term study of new antihypertensive drugs according to the programme worked out by the Cooperative Trial of Drugs for the Prevention of Arterial Hypertension (CTDPAH) is based on a system approach including observation of patients with essential hypertension and secondary hypertension with different initial level of arterial pressure, simultaneous study of the effect of three basic antihypertensive drugs, and evaluation of the action of these drugs with the application of a stepwise scheme. The study is long-term, cooperative (multicentral) and controlled. The first results in 387 patients, obtained in the curse of 5 to 8 months, showed that in nearly half of the patients with stable, mild or moderate hypertension it is possible to use prolonged antihypertensive monotherapy, with one third of these cases showing normalization of pressure, and other third partial effect. Most promising for long-term antihypertensive prevention proves to be prazosin, an alpha 1-postsynaptic adrenoreceptor blocking drug, which in contrast to propranolol has a marked antiatherogenic effect on blood plasma lipoproteins.

Clinical Trials as Topic↗
PubMed1987

[Angina of effort as an unfavorable prognostic factor].

A seven-year prospective study of a random 10% sample of a population of 50- to 59-year-old males from one municipal district in Moscow is reported. Mortality was reviewed among patients with complicated angina pectoris, i.e. those exhibiting other coronary symptoms as well, and among patients with uncomplicated angina as the primary and only sign of coronary heart disease (CHD). At long-term follow-up, the diagnosis of both varieties of angina is associated with aggravated vital prognosis. Some correlations between CHD risk factors and mortality are presented for both groups of anginal patients.

Aged↗
PubMed1986

The effect of oral verapamil therapy on antipyrine clearance.

The influence of chronic verapamil treatment on antipyrine elimination was studied in eight angina patients. Antipyrine half-life (mean +/- s.d.) was 13.1 +/- 1.15 h at the start of therapy and 16.6 +/- 3.05 h (P less than 0.05) during chronic oral administration of verapamil (80-120 mg four or three times daily for 4 to 7 months). There was a significant decrease in antipyrine clearance (mean +/- s.d, 43.2 +/- 16.8 ml min-1 vs 28.7 +/- 16.6 ml min-1, P less than 0.01) while the change of distribution volume was insignificant. Verapamil elimination was also found to be impaired after chronic dosing as compared to single administration. Half-lives measured from the concentration vs time and urinary excretion rate vs time curves were both prolonged and oral clearance was decreased. Our results suggest that the inhibition of drug-metabolizing enzymes accounts for the impairment of verapamil elimination on chronic administration.

Administration, Oral↗
PubMed1986

[Clinico-pharmacological study of a new Russian anti-angina preparation dinitrosorbilong].

Eighty patients with ischemic heart disease and stable angina pectoris of effort were examined for the efficacy of dinitrosorbilong (DNL), a new long-acting drug based on isosorbide dinitrate (ID). The anti-ischemic effect of DNL appraised with the aid of repeated exercise lasted about 8h, which was on the average 4 h longer as compared with the duration of the anti-ischemic effect of ID tablets. The regular intake of DNL favoured an appreciable decrease in the number of angina pectoris attacks making it possible to lower nitroglycerin consumption. DNL was well tolerated by the patients.

Administration, Oral↗
PubMed1986

[Dinitrosorbilong--a new Soviet anti-angina preparation. Its comparative pharmacodynamic, pharmacokinetic and clinical study].

The efficacy of dinitrosorbilong (DNL)--a new long-acting isosorbid dinitrate (IDN) preparation applied to the gum--was evaluated in 72 coronary patients with stable angina of effort. Repeated treadmill tests revealed antianginal effect of DNL exceeding 8 hours. The degree and duration of DNL action significantly surpassed those of conventional oral IDN tablets and of some other long-acting IDN preparations. The results of pharmacokinetic studies show that DNL bioavailability is 491 +/- 240% as compared to conventional oral IDN tablets. Regular 7-day DNL administration resulted in a significant decrease in the frequency of anginal attacks and in the daily consumption of nitroglycerin tablets as compared not only to the control period but also to the period of conventional IDN tablet therapy.

Angina Pectoris↗
PubMed1986

Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris.

Pharmacokinetics of verapamil and of its three primary metabolites [norverapamil, 2-(3,4-dimethoxyphenyl)-2-isopropyl-6-azaheptanitrile (D-617) and 2-(3,4-dimethoxyphenyl)-2-propylamino-3-methylbutyronitrile (D-260)] was studied after oral administration in 7 patients with stable angina pectoris. Serum levels of metabolites were found to be in the same range as that of the intact drug. Areas under the serum concentration time curves of each metabolite were higher and serum half-lives were significantly longer than those of verapamil. Half-life values obtained from urinary excretion data and from serum levels did not differ for the metabolites, but for the unchanged drug, the half-life from urinary excretion data was longer. Cumulative urinary excretion of verapamil, norverapamil, D-617 and D-620 up to 48 h postdose was averaged to 1%, 2.2%, 11.4%, and 6.7% of the dose administered, respectively. The extent of verapamil bioavailability was directly measured in one patient receiving an intravenous dose as well as an oral one and was found to be 42.3%. In other patients, bioavailability was assessed by means of a regression equation relating the reciprocal of bioavailability and oral clearance of the drug, and was averaged at 35.1%. The possibilities of contribution of the metabolites to verapamil effects in patients were discussed.

Administration, Oral↗
PubMed1985

[Screening of single doses of nitrates, calcium antagonists and beta-adrenoblockaders in patients with stenocardia of effort by using pharmacodynamic treadmill studies].

Standard single doses of nitrates, Ca-antagonists and beta-adrenoblockers were studied and compared in 37 patients presenting with stable angina pectoris of effort by repeated treadmill tests coupled with ECG monitoring. The use of isosorbide dinitrate (10 mg), nifedipin (20 mg) and propranolol (40 mg) enabled the effective drug to be screened in 86% of patients. Eleven per cent more of patients responded to the raising of the drug dosage. Isosorbide dinitrate was found to be the most effective in 27% of cases, nifedipin in 19%, and propranolol in 11%. The effect of 2 to 3 drugs was similar in 40% of patients. The data obtained during the screening of the most effective drug in 13 patients, performed by two different methods (treadmill pharmacodynamic and pair bicycle ergomentry tests showed a good agreement in the majority of cases).

Adrenergic beta-Antagonists↗
PubMed1985

[Possibility of developing tolerance to the anti-anginal effect of isosorbide dinitrate and verapamil].

Using exercise tests in 22 patients with stable angina of effort, the authors studied the possibility of the development of tolerance to the antianginal effect of isosorbide dinitrate (ID) and verapamil (VP). Within 6-12 weeks of the regular intake of ID, 5 (26%) patients developed complete tolerance, 6 (32%) partial tolerance to the drug. In 8 (42%) patients the effect of ID remained stable. A six-week administration of VP was accompanied by no signs of tolerance to the drug even in the patients who showed tolerance to ID.

Adult↗
PubMed1985

[Cooperative study on the long-term use of anti-anginal preparations (methodologic questions)].

The development of a national collaborative program for the study of long-term effects of antianginal drugs initiated for the first time in our country is reported. The present communication is concerned with methodological approaches to the study. The collaborative effort has enabled a basically new scale of research. The principal methodological problems discussed are: how to select antianginal drugs; how to assess drug tolerance; and, possible changes in pharmacokinetic parameters of antianginal drugs used on a long-term basis. Studies along these lines are expected to contribute to the development of optimum regimens of antianginal treatment.

Adult↗